Paulo Godoy

Dr. Paulo Godoy


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
AMAna P. Montaldi
Ana P. Montaldi
PGPaulo Godoy
Paulo Godoy
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo 

16 June 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
PGPaulo Godoy
Paulo Godoy
AKAli Pour Khavari
Ali Pour Khavari
MRMarzia Rizzo
Marzia Rizzo
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo 
SHSiamak Haghdoost
Siamak Haghdoost
The presence of glioma stem cells (GSCs), which are enriched in neurospheres, may be connected to the radioresistance of glioblastoma (GBM) due to their enhanced antioxidant defense and elevated DNA repair capacity. The aim was to evaluate the responses to different radiation qualities and to reduce radioresistance of U87MG cells, a GBM cell line. U87MG cells were cultured in a 3D model and irradiated with low (24 mGy/h) and high (0.39 Gy/min) dose rates of low LET gamma and high LET carbon ions (1-2 Gy/min). Thereafter, expression of proteins related to oxidative stress response, extracellular 8-oxo-dG, and neurospheres were determined. LD50 for carbon ions was significantly lower compared to LD50 of high and low dose rate gamma radiation. A significantly higher level of 8-oxo-dG was detected in the media of cells exposed to a low dose rate as compared to a high dose rate of gamma or carbon ions. A downregulation of oxidative stress proteins was also observed (NRF2, hMTH1, and SOD1). The NRF2 gene was knocked down by CRISPR/Cas9 in neurosphere cells, resulting in less self-renewal, more differentiated cells, and less proliferation capacity after irradiation with low and high dose rate gamma rays. Overall, U87MG glioma neurospheres presented differential responses to distinct radiation qualities and NRF2 plays an important role in cellular sensitivity to radiation.

1 August 2013 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
PGPaulo Godoy
Paulo Godoy
SMS.S. Mello
S.S. Mello
DMD.A.R. Magalhães
D.A.R. Magalhães
FDF.S. Donaires
F.S. Donaires
PNPatricia Nicolucci
Patricia Nicolucci
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo 

7 September 2020 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
AMAna P. Montaldi
Ana P. Montaldi
SLSarah C.G. Lima
Sarah C.G. Lima
PGPaulo Godoy
Paulo Godoy
DXDanilo J. Xavier
Danilo J. Xavier
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo 
Information on the mechanisms that are associated with tumor resistance has the potential to provide the fundamental basis for novel therapeutic strategies. In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly‑ADP‑ribose polymerase inhibitor (PARPi) remain largely unidentified. In this context, the influence of MGMT (O6‑methylguanine DNA methyltransferase) and PTEN (phosphatase and tensin homologue deleted on chromosome ten) has been studied in addition to the occurrence of synthetic lethality involving PTEN and PARPi. The present study investigated whether PARP‑1 inhibition by NU1025 may increase the cytotoxicity of TMZ‑induced lesions in GBM cells, and whether these mechanisms can be influenced by MGMT and PTEN status. The impact of PTEN deficiency in repair pathways, and the effects of PARP‑1 inhibition and PTEN silencing, in terms of synthetic lethality, were also assessed. NU1025 combined with TMZ effectively sensitized TMZ‑resistant cells (T98G PTEN‑mutated and LN18 PTEN‑wild‑type) and TMZ‑sensitive cells (U251MG PTEN‑mutated), in contrast to NU1025 alone. However, the sensitizing effects were not observed in U87MG (PTEN‑mutated) cells, suggesting that specific genetic alterations may influence the response to drug treatment. The sensitizing effects occurred independently of MGMT activity, which was evaluated in O6‑BG‑treated cells. PTEN silencing using small interfering (si)RNA did not sensitize PTEN‑proficient cells to TMZ + NU1025, or NU1025 alone, indicating an absence of synthetic lethality. The responses to TMZ + NU1025 involved antiproliferative activity, G2/M arrest, double strand breaks and the induction of apoptosis. Following 20 days of recovery after three consecutive days of TMZ treatment, TMZ‑resistant cells were observed. However, when TMZ was combined with NU1025, the viability of T98G and LN18 cells was extremely decreased, indicating a lethal drug combination. Therefore, independently of MGMT proficiency and PTEN status, TMZ combined with PARPi may be a promising strategy that can be used to overcome TMZ acquired resistance in GBM cells.

27 February 2017 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
FDFlávia S. Donaires
Flávia S. Donaires
PGPaulo Godoy
Paulo Godoy
GLGiovana S. Leandro
Giovana S. Leandro
Denis PuthierDenis Puthier
Denis Puthier
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo 
BACKGROUND: Glioblastoma is considered to the most common and malignant brain tumor in adults. Patients have a median survival of approximately one year from diagnosis due to poor response to therapy. OBJECTIVE: We applied bioinformatics approaches t

11 July 2017 in Transition Metal Chemistry
Verified
Journal Article
Closed access
PDF file
TMThales R. De Moura
Thales R. De Moura
SCSahra L. Cavalcanti
Sahra L. Cavalcanti
PGPaulo Godoy
Paulo Godoy
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo 
FRFillipe V. Rocha
Fillipe V. Rocha
ANAdelino Vieira de Godoy Netto
Adelino Vieira de Godoy Netto